← Back to Clinical Trials
Recruiting NCT07592871

NCT07592871 Cohort of Lower-Extremity Sports Injuries and Degeneration(Yongjiang Cohort)

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07592871
Status Recruiting
Phase
Sponsor Ningbo No.2 Hospital
Condition Osteoarthritis (OA) of the Knee
Study Type OBSERVATIONAL
Enrollment 500 participants
Start Date 2026-06-01
Primary Completion 2028-05-31

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age 90 Years
Study Type OBSERVATIONAL
Interventions
Routine Clinical Care

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 500 participants in total. It began in 2026-06-01 with a primary completion date of 2028-05-31.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

This is an observational cohort study conducted at Ningbo No. 2 Hospital. The study will include patients with knee-related sports injuries or degenerative knee conditions who receive routine clinical care. The purpose is to build a standardized real-world clinical cohort and evaluate knee injury, degeneration, recovery, and long-term outcomes. After informed consent, participants will undergo baseline data collection, including medical history, laboratory tests, questionnaires, X-ray and MRI imaging, and functional assessments. Patients younger than 50 years will mainly be assessed for sports injury and functional recovery, while patients aged 50 years or older will receive additional sarcopenia-related assessments such as grip strength, DXA testing, and gait evaluation. No experimental treatment, randomization, or intervention will be assigned. Participants will be followed at about 6, 12, and 24 months after treatment or surgery to assess knee function, imaging changes, reinjury, reoperation, pain, quality of life, falls, and functional decline. The study plans to enroll about 500 participants.

Eligibility Criteria

Inclusion Criteria: * Patients who plan to receive relevant clinical evaluation or treatment at Ningbo No. 2 Hospital and are able to complete baseline assessment. * Patients with a clinical diagnosis of knee-related injury or degenerative knee disease. * Patients who are willing to provide informed consent and participate in follow-up. Exclusion Criteria: * Patients who are unable to complete the core baseline assessments or have substantial missing key clinical information. * Patients with severe comorbid conditions or cognitive impairment that may affect assessment of the main outcomes or prevent participation in follow-up. * Patients who are considered by the investigator to be unsuitable for inclusion in this cohort.

Contact & Investigator

Central Contact

Yi Yuan, MD

✉ yct1124@alumni.sjtu.edu.cn

📞 +86 18858234093

Frequently Asked Questions

Who can join the NCT07592871 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, up to 90 Years, studying Osteoarthritis (OA) of the Knee. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07592871 currently recruiting?

Yes, NCT07592871 is actively recruiting participants. Contact the research team at yct1124@alumni.sjtu.edu.cn for enrollment information.

Where is the NCT07592871 trial being conducted?

This trial is being conducted at Ningbo, China.

Who is sponsoring the NCT07592871 clinical trial?

NCT07592871 is sponsored by Ningbo No.2 Hospital. The trial plans to enroll 500 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: September 2026  ·  Data Methodology